Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Paola Storti, Valentina Marchica, Rosanna Vescovini, Valentina Franceschi, Luca Russo, Laura Notarfranchi, Vincenzo Raimondi, Denise Toscani, Jessica Burroughs-Garcìa, Federica Costa, Benedetta Dalla Palma, Nicolas Thomas Iannozzi, Gabriella Sammarelli, Gaetano Donofrío, Nicola Giuliani
Abstract
T cells were found in MM patients as compared to patients with monoclonal gammopathy of undetermined significance. We found that a heterologous booster immunization improved SARS-CoV-2 spike humoral and cellular responses in newly diagnosed MM (MMD) patients and in most, but not all, MMR patients. After the booster dose, a significant increase of the neutralizing antibody titers against almost all the analyzed variants was achieved in MMD. However, in MMR patients, Omicron retained a negative impact on neutralizing ability, suggesting further approaches to potentiating the effectiveness of SARS-CoV-2 vaccination in these patients.